Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1997 3
1998 3
2001 3
2002 1
2004 3
2005 4
2006 3
2007 4
2008 5
2009 4
2010 9
2011 9
2012 6
2013 7
2014 11
2015 21
2016 18
2017 19
2018 20
2019 11
2020 16
2021 20
2022 17
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Matsuzaki S, et al. Gynecol Oncol. 2021 Feb;160(2):586-601. doi: 10.1016/j.ygyno.2020.10.043. Epub 2020 Nov 9. Gynecol Oncol. 2021. PMID: 33183764 Review.
Uterine carcinosarcoma (UCS) is a biphasic aggressive high-grade endometrial cancer in which the sarcoma element has de-differentiated from the carcinoma element. ...
Uterine carcinosarcoma (UCS) is a biphasic aggressive high-grade endometrial cancer in which the sarcoma element has de-differ …
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Nishikawa T, et al. J Clin Oncol. 2023 May 20;41(15):2789-2799. doi: 10.1200/JCO.22.02558. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977309 Free PMC article.
PURPOSE: To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2. P …
PURPOSE: To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth facto …
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A, Nishikawa T, Yoshida H, Mizoguchi C, Kitadai R, Yamamoto K, Yazaki S, Kojima Y, Ishikawa M, Kato T, Yonemori K. Saito A, et al. Gynecol Oncol. 2023 Sep;176:115-121. doi: 10.1016/j.ygyno.2023.07.010. Epub 2023 Jul 26. Gynecol Oncol. 2023. PMID: 37506533
This widespread FRalpha expression suggests that FRalpha-targeted therapies may hold promise for the treatment for gynecologic carcinosarcoma. However, in uterine carcinosarcoma, no significant relationship was observed between FRalpha expression and clinicopatholog …
This widespread FRalpha expression suggests that FRalpha-targeted therapies may hold promise for the treatment for gynecologic carcinosarcom …
Uterine carcinosarcomas: From pathology to practice.
Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, Levine DA, Dowdy SC, Klopp A, Powell MA, Thaker PH. Toboni MD, et al. Gynecol Oncol. 2021 Jul;162(1):235-241. doi: 10.1016/j.ygyno.2021.05.003. Epub 2021 May 21. Gynecol Oncol. 2021. PMID: 34030871 Review.
OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare but aggressive cancer. In early-stage disease data guiding treatment is sparse. ...
OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare but aggressive cancer. In early-stage disease data guiding treatment is spar …
Uterine Carcinosarcomas - Diagnosis and Management.
Denschlag D, Ulrich UA. Denschlag D, et al. Oncol Res Treat. 2018;41(11):675-679. doi: 10.1159/000494335. Epub 2018 Oct 13. Oncol Res Treat. 2018. PMID: 30317231 Review.
The clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma will be discussed in this review....
The clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma will be discussed in this review....
Adjuvant chemotherapy in endometrial cancer.
Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, Casado Saenz E. Gómez-Raposo C, et al. Cancer Chemother Pharmacol. 2020 Mar;85(3):477-486. doi: 10.1007/s00280-019-04027-6. Epub 2020 Jan 16. Cancer Chemother Pharmacol. 2020. PMID: 31950214 Review.
Early-stage clear-cell carcinoma patients might not benefit for adjuvant CT, but stage III patients might benefit from the combination of CT and EBRT. Stage I-III uterine carcinosarcoma patients might be offered adjuvant CT followed by RT or as a "sandwich" regimen. …
Early-stage clear-cell carcinoma patients might not benefit for adjuvant CT, but stage III patients might benefit from the combination of CT …
Adjuvant therapy and prognosis in uterine carcinosarcoma.
Chiang CY, Huang HJ, Chang WY, Yang LY, Wu RC, Wang CC, Tung HJ, Chao A, Lai CH. Chiang CY, et al. J Formos Med Assoc. 2021 Nov;120(11):1977-1987. doi: 10.1016/j.jfma.2021.04.016. Epub 2021 May 13. J Formos Med Assoc. 2021. PMID: 33992491 Free article.
PURPOSE: To investigate the prognostic factors and impact of adjuvant treatment on uterine carcinosarcoma (UCS). METHODS: A retrospective review of UCS patients treated between 2005 and 2019 was conducted. ...
PURPOSE: To investigate the prognostic factors and impact of adjuvant treatment on uterine carcinosarcoma (UCS). METHODS: A re …
Review literature on uterine carcinosarcoma.
Singh R. Singh R. J Cancer Res Ther. 2014 Jul-Sep;10(3):461-8. doi: 10.4103/0973-1482.138197. J Cancer Res Ther. 2014. PMID: 25313723 Free article. Review.
The exact nature and prognosis was not clear in the past. It is believed that uterine carcinosarcoma have a Mullerian duct origin and have a capacity to differentiate into various mesenchymal and epithelial components. ...Here we are reviewing old concepts about the …
The exact nature and prognosis was not clear in the past. It is believed that uterine carcinosarcoma have a Mullerian duct ori …
Uterine sarcomas: clinical presentation and MRI features.
Santos P, Cunha TM. Santos P, et al. Diagn Interv Radiol. 2015 Jan-Feb;21(1):4-9. doi: 10.5152/dir.2014.14053. Diagn Interv Radiol. 2015. PMID: 25347940 Free PMC article. Review.
Due to their distinct clinical and biological behavior, the International Federation of Gynecology and Obstetrics introduced a new staging system for uterine sarcomas in 2009, categorizing uterine carcinosarcoma as a variant of endometrial carcinoma, rather than a p …
Due to their distinct clinical and biological behavior, the International Federation of Gynecology and Obstetrics introduced a new staging s …
Uterine carcinosarcoma: A 10-year single institution experience.
Terblanche L, Botha MH. Terblanche L, et al. PLoS One. 2022 Jul 21;17(7):e0271526. doi: 10.1371/journal.pone.0271526. eCollection 2022. PLoS One. 2022. PMID: 35862371 Free PMC article.
OBJECTIVE: This study aimed to determine 5-year progression-free and overall survival in patients with uterine carcinosarcoma, to determine clinical and surgical-pathologic features, to recognize patterns of recurrence and to identify prognostic factors influencing …
OBJECTIVE: This study aimed to determine 5-year progression-free and overall survival in patients with uterine carcinosarcoma, …
200 results